News Website

Endometrial NCOR1 deficiency contributes to implantation failure in endometriosis-associated infertility.

Endometriosis-associated infertility is a complex condition in which the presence of endometrial-like tissue disrupts implantation and early pregnancy. Epigenetic regulators are critical for implantation and decidualization, yet their contribution to …

Published: April 12, 2026, midnight

Read Full Article

Epigenetics Molecular genetics Molecular mechanism of gene regulation

Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer - Cure Today

Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer Cure Today

Published: April 11, 2026, 9:14 p.m.

Read Full Article

Black Women With Endometrial Cancer Completed Treatment More With Peer Support - CancerNetwork

Black Women With Endometrial Cancer Completed Treatment More With Peer Support CancerNetwork

Published: April 11, 2026, 8:04 p.m.

Read Full Article

Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive

Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer OncLive

Published: April 11, 2026, 6:14 p.m.

Read Full Article

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma OncLive

Published: April 11, 2026, 4:04 p.m.

Read Full Article

BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative

BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer Quiver Quantitative

Published: April 11, 2026, 11:10 a.m.

Read Full Article

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times

Published: April 11, 2026, 11:01 a.m.

Read Full Article

In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

In recurrent endometrial cancer, BioNTech drug held off progression 8 months Stock Titan

Published: April 11, 2026, 11 a.m.

Read Full Article

Progesterone in MHT for Protection Against Endometrial Cancer - The Vajenda

Progesterone in MHT for Protection Against Endometrial Cancer The Vajenda

Published: April 11, 2026, 9:17 a.m.

Read Full Article

New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer - StreetInsider

New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer StreetInsider

Published: April 10, 2026, 11:01 a.m.

Read Full Article

Latest Articles

Endometrial NCOR1 deficiency contributes to implantation failure in endometriosis-associated infertility.

Verzenio Plus Letrozole Shows Durable Responses in Advanced Endometrial Cancer - Cure Today

Black Women With Endometrial Cancer Completed Treatment More With Peer Support - CancerNetwork

Trastuzumab Pamirtecan Elicits Responses in HER2-Expressing Advanced/Metastatic Endometrial Cancer - OncLive

Abemaciclib Plus Letrozole Displays Durable Activity in Advanced/Recurrent Endometrioid Endometrial Carcinoma - OncLive

BioNTech's Trastuzumab Pamirtecan Achieves Positive Phase 2 Results in Advanced HER2-Expressing Endometrial Cancer - Quiver Quantitative

BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer - The Manila Times

In recurrent endometrial cancer, BioNTech drug held off progression 8 months - Stock Titan

Progesterone in MHT for Protection Against Endometrial Cancer - The Vajenda

New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer - StreetInsider

Subscribe to Our Newsletter